Fda authorizes further nurown® dosing under expanded access program

New york, dec. 27, 2021 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of cellular therapies for neurodegenerative diseases, today announced plans for a dosing extension of nurown® for participants who completed the expanded access protocol (eap). the u.s. food and drug administration (fda) recommended that brainstorm submit an eap protocol amendment to provide additional dosing for these participants.
BCLI Ratings Summary
BCLI Quant Ranking